Feb 27, 2017 Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months Learn More
Feb 22, 2017 Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma Learn More
Feb 13, 2017 UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference Learn More